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Abstract
Objective: In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are
specifically targeting distinct groups of mutations, such as deletions eligible for skipping of individual exons. The aim of this
observational study was to establish whether patients with distinct groups of mutations have different profiles of changes
on the 6 minute walk test (6MWT) over a 12 month period.
Methods: The 6MWT was performed in 191 ambulant DMD boys at baseline and 12 months later. The results were analysed
using a test for heterogeneity in order to establish possible differences among different types of mutations (deletions,
duplications, point mutations) and among subgroups of deletions eligible to skip individual exons.
Results: At baseline the 6MWD ranged between 180 and 560,80 metres (mean 378,06, SD 74,13). The 12 month changes
ranged between 2325 and 175 (mean 210.8 meters, SD 69.2). Although boys with duplications had better results than
those with the other types of mutations, the difference was not significant. Similarly, boys eligible for skipping of the exon
44 had better baseline results and less drastic changes than those eligible for skipping exon 45 or 53, but the difference was
not significant.
Conclusions: even if there are some differences among subgroups, the mean 12 month changes in each subgroup were all
within a narrow Range: from the mean of the whole DMD cohort. This information will be of help at the time of designing
clinical trials with small numbers of eligible patients.
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Introduction
In the last few years several therapeutical approaches have
become available for patients affected by Duchenne muscular
dystrophy (DMD) [1–4]. Some of these approaches are specifically
targeting distinct types of mutations, such as nonsense mutations,
causing premature stop codons, or specific deletions as in exon
skipping studies [5–9]. Because of this, the number of patients
eligible for each study is limited to those having the targeted
mutations and is further restricted by other inclusion criteria such
as age or functional level. In the first studies using antisense
oligonucleotides, the first exon to be targeted was exon 51 as this
had the highest number of patients eligible for its skipping [5,8,10–
12] (17% of the deletions reported in the Leiden database [13]).
Ongoing or planned studies are targeting for skipping other exons
(exons 44,53,45) with a lower number of potentially eligible DMD
boys and increasing difficulties in recruiting sufficient numbers to
allow placebo groups. This has raised the question whether natural
history data could be used as controls and, more generally,
whether individual groups of mutations have distinct profiles of
progression that may be different from what observed in the whole
DMD cohort.
Longitudinal natural history data collected in relatively large
cohorts of DMD ambulant boys [14–16] are available but no
systematic study has been performed to explore functional changes
in individual groups of mutations.
The aim of this study was to report 12 month changes of
6MWT in a large cohort of DMD ambulant patients subdivided
according to groups of mutations.
Subjects and Methods
The patients reported are part of longitudinal multicentric
cohort studies involving 13 tertiary neuromuscular centers in Italy
and one centre in Belgium. Patients were recruited from January
2008 and followed for at least one year. The study was approved
by the Ethical Committees of the Catholic University, Rome,
Ospedale Bambino Gesu`, Rome, Istituto Mondino, Pavia, Gaslini
Institute, Genova, Besta Institute, Milan, Stella Maris Institute,
Pisa, Ospedale Maggiore, Bologna, University of Napoli, Univer-
sity of Messina, University of Torino, University of Padova,
University of Milano, University of Leuven. As the assessment was
already part of the clinical routine in all centers, with the approval
of the Ethics Committees, verbal consent to record the
anonymized data in a database was obtained by the parents for
the boys under age.
Patient inclusion criteria at baseline were: genetically proven
DMD diagnosis, patient still ambulant and able to walk
independently for at least 100 meters, no severe or moderate
learning difficulties or behavioral problems. Genetic and treatment
information were collected and classified following the criteria
used in our previous studies on the same cohort [15,16]. The study
was approved by the ethical committee of each center.
We broadly subdivided our cohort into patients on steroids and
those with no steroid treatment, this included boys who had never
been on steroids and others who had used them for less than a year
and had stopped treatment at least one year before the study.
6MWT
6MWT was performed in all DMD ambulant boys according to
the ATS guidelines [17], modified by having two examiners, one
recording time and distances and one staying close to the patient
for safety issues. As part of the routine assessments in all centers
patients are seen at least once every 12 months. Data were
collected from the first assessment after recruitment (baseline) and
from the 12 month assessment. Details of the training and
interobserver reliability have been previously reported [15,16].
Statistical analysis
The 6MWT was evaluated longitudinally over a 12-month
period of time. Summary statistics (N, mean, SD, Range:) were
used. Both baseline 6MWT and its 12 months change were
symmetrically distributed around their mean value and the
distribution is close to a normal one.
Furthermore, the 6 minute walk distance (6MWD) data were
converted to a percent predicted (%-predicted) value according to
the age and height based Geiger equation (% Gei-
ger = 196.72+39.81*age2(1.36*age2)+132.28 *height(m)) as has
been proposed to account for growth and maturational influences
[18,19] The same descriptive statistics were calculated as for the
6MWD.
Both 6MWD and % predicted data were subdivided according
to the type of deletion (deletions, duplications, point mutations).
Boys with deletions were further subdivided identifying those
carrying mutations eligible for skipping of the exons that,
according to the Leiden database, are more frequent in the
DMD population (see Table S1).
An ANOVA model adjusting for baseline age was used to assess
heterogeneity among groups of 6MWD baseline values and its 12
months change. The test was performed on the whole cohort and
in the group who had deletions. As the recent clinical trials only
include patients who are on steroids we also performed the test for
heterogeneity excluding the boys who were not on steroids.
Results
One hundred and ninety-one patients fulfilled the inclusion
criteria and entered the study. All had out of frame mutations
and/or absent dystrophin on muscle biopsy.
6MWT in DMD
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113 of these patients have already been reported in our previous
studies reporting follow up data in ambulant DMD boys [15]. Of
the 191 boys, 176 were on steroids, and 15 were not on steroids.
132 had deletions, 15 had duplications and 44 point mutations.
The distribution of groups of deletions according to their eligibility
to exon skipping are shown in table 1 and in the online additional
table.
6MWT
Four children lost the ability to perform the test within 12
months. At baseline the 6MWD ranged between 180 and
560,80 metres (mean 378,06, SD 74,13). Converting the 6MWD
to % predicted values, based on the Geiger equation, the baseline
values ranged between 28.31 and 119.49 with an average of 66.5
(SD 14.71).
The 12 month changes ranged between 2325 and 175 with an
average of 210.8 meters (SD 69.2). The 12 month % predicted
ranged between 271 and 39 with an average of 24 (SD 12.76)
(table 1)
Type of mutations
Table 1 show details of the 6MWD at baseline and of the 12
months changes. There was no significant difference between
deletions, duplications and point mutations neither at baseline
(Figure S1a) nor in the 12 month changes (Figure S1b)
Groups of deletions and 6MWT
Figure 1 shows details of the 6MWD at baseline in the different
subgroups of deletions identified according to their eligibility to
skip specific exons. A statistically significant heterogeneity was
detected among groups with a deletion (p= 0.03) (figure 2). The
heterogeneity was no longer significant when baseline values were
converted to % predicted (p = 0.06).
Figure 3 shows details of the 12 month changes in the 6MWD in
the different subgroups of deletions identified according to their
eligibility to skip specific exons.
On the test for heterogeneity there were no differences among
the groups (p = 0.53) also adjusting for age (p= 0.70). The
heterogeneity among the groups is not significant also when only
the groups with a deletion were considered (p= 0.86 for
heterogeneity adjusting for age) (figure 4).
This was true also when the raw scores were converted in %
predicted (p = 0.33 for all the groups and p=0.47 within the
deletion group).
The results of the test after excluding the boys who were not on
steroids showed similar results to the whole cohort.
Discussion
Recent natural history longitudinal studies using the 6MWT
and the NSAA to measures changes in ambulant DMD boys have
reported a wide variability of such changes over 12 and 24 months
[15,16]. The recent advent of therapeutical approaches targeting
specific groups of mutations has highlighted the need to establish
whether some of the variability observed may be due to the
different mutations in the dystrophin gene.
In our cohort boys with duplications and point mutations (single
nucleotide substitutions) had better overall scores than those with
deletions at baseline but the difference was not significant. The 12
month changes showed even less difference among the three types
Table 1. Baseline and 12 month changes of 6MWD in the whole DMD cohort and in different mutation subgroups.
Age 6MWD Baseline
6MWD 12 month
changes % predicted Baseline
% predicted 12 month
changes
Whole cohort (n = 191) Range: 3,2 to 15,0
Mean 7,90 SD 2,23
Range: 185 to 560,80
Mean 378,06 SD 74,13
Range: 2325 to 175
Mean 210,19 SD 69,33
Range: 0,28 to 1,19
Mean 0,66 SD 0,15
Range: 271 to 39
Mean 23,88 SD 12,57
Below age 7 (n = 80) Range: 3,2 to 7
Mean 5,84; SD 0,9
Range: 215 to 521,50
Mean 383,09 SD 64,4
Range: 295 to 175
Mean 27,37 SD 53,02
Range: 0,39 to 1,19
Mean 0,73 SD 0,13
Range: 271 to 39
Mean 1,09 SD 13,81
Above age 7 (n = 111) Range: 7,1 to 15,0
Mean 9,38 SD 1,7
Range: 185 to 560,80
Mean 374,43 SD 80,5
Range: 2325 to 102
Mean 237,25 SD 67,21
Range: 0,28 to 0,96
Mean 0,62 SD 0,14
Range: 250 to 16
Mean 27,36 SD 10,25
Duplications (n = 15) Range: 5,9 to 15
Mean 8,6 SD 2,28
Range: 187 to 521
Mean 420,26 SD 85,3
Range: 287 to 102
Mean 4,37 SD 54,14
Range: 0,29 to 0,97
Mean 0,72 SD 0,17
Range: 215 to 14
Mean 21,53 SD 8,40
Point mutations (n = 44) Range: 4,4 to 12,6
Mean 7,5 SD 1,9
Range: 250 to 560,80
Mean 393,62 SD 70,53
Range: 2135 to 164
Mean 20,84 SD 53,60
Range: 0,40 to 1,19
Mean 0,70 SD 0,16
Range: 224 to 26
Mean 22,65 SD 8,67
All deletions (n = 132) Range: 3,2 to 13,7
Mean 7,96 SD 2,32
Range: 185 to 557,50
Mean 368,07 SD 71,93
Range: 2325 to 175
Mean 214,95 SD 75,09
Range: 0,28 to 0,95
Mean 0,65 SD 0,14
Range: 271 to 39
Mean 24,41 SD 13,83
*Deletions eligible for
skipping exon 44 (n = 18)
Range: 4,6 to 13
Mean 8,2 SD 2,6
Range: 300 to 557,50
Mean 398,16 SD 65,28
Range: 284 to 118
Mean 211,78 SD 54,89
Range: 0,51 to 0,95
Mean 0,68 SD 0,11
Range: 216 to 15
Mean 24 SD 8,22
Deletions eligible for
skipping exon 45 (n = 15)
Range: 5 to 11,4
Mean 8,4 SD 2,35
Range: 187 to 485
Mean 334,46 SD 72,46
Range: 2325 to 135
Mean 221,6 SD 111,76
Range: 0,29 to 0,92
Mean 0,59 SD 0,16
Range: 271 to 21
Mean 210,16 SD 23,35
*Deletions eligible for
skipping exon 46 (n = 7)
Range: 4,6 to 9,9
Mean 7,3 SD 2,37
Range: 185 to 419
Mean 335,30 SD 85,47
Range: 238 to 31
Mean 0,83 SD 24,51
Range: 0,28 to 0,85
Mean 0,59 SD 0,19
Range: 27 to 1
Mean 21,83 SD 2,93
Deletions eligible for
skipping exon 50 (n = 9)
Range: 4,1 to 10,8
Mean 7,4 SD 2,33
Range: 256 to 477,50
Mean 358,63 SD 77,11
Range: 255 to 83
Mean 27,56 SD 44,84
Range: 0,49 to 0,79
Mean 0,65 SD 0,11
Range: 210 to 11
Mean 23,63 SD 6,97
**Deletions eligible for
skipping exon 51 (n = 27)
Range: 3,6 to 12,5
Mean 7,7 SD 2,17
Range: 200 to 462
Mean 362,66 SD 62,26
Range: 2246 to 99
Mean 221,59 SD 76,33
Range: 0,31 to 0,79
Mean 0,63 SD 0,12
Range: 240 to 13
Mean 25,19 SD 11,62
**Deletions eligible for
skipping exon 53 (n = 28)
Range: 5 to 13
Mean 8,6 SD 1,96
Range: 189 to 458
Mean 344,11 SD 67,16
Range: 2240 to 127
Mean 234,18 SD 77,99
Range: 0,3 to 0,83
Mean 0,60 SD 0,13
Range: 237 to 20
Mean 26,89 SD 12,10
*4 boys had deletion of exon 45 and were included both in the group eligible for skipping 44 and 46.
**x boys had deletion of exon 52 and were included both in the group eligible for skipping 51 and 53.
doi:10.1371/journal.pone.0083400.t001
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of mutations than at baseline. These findings are in agreement
with previous studies, also reporting that the type of mutations
does not influence clinical evolution [20]. In our cohort the
incidence of point mutations was higher than that reported in the
Leiden database [13] and reflect a general trend also observed in
our Italian registry, that also includes younger and non ambulant
boys not included in this study (data not shown).
In this paper we were specifically interested to the groups of
deletions identified according to their eligibility to skip individual
exons. In agreement with the Leiden database [13], we also found
that the subgroups of mutations eligible for skipping exons 51, 53,
44 and 45 were the most frequent [13]. In our cohort however,
those eligible for skipping exon 53 were relatively more frequent
and those eligible for skipping of exon 45 less frequent than in the
Leiden database.
The results of our study highlighted two important findings:
there are some differences among individual subgroups but, on the
test for heterogeneity this difference was not significant, neither at
baseline nor on the 12 month changes.
More specifically the subgroup eligible for skipping exon 44 had
overall better baseline values of 6MWD than the other subgroups,
and the difference was also observed when the raw scores were
converted to % predicted. On the 12-month changes the
difference was smaller. The subgroup eligible for skipping exon
Figure 2. Mean raw scores (left panel) and % predicted (right panel) of 6MWD in individual subgroups.
doi:10.1371/journal.pone.0083400.g002
Figure 1. Baseline values of 6MWD: in each graph the individual results obtained in individual subgroups (eligible for skipping
exon 44, 45, 51 and 53) are plotted against those found in the whole DMD color.
doi:10.1371/journal.pone.0083400.g001
6MWT in DMD
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45 and 53 in contrast appeared to have overall lower baseline
values and more negative 12 month changes than the other
subgroups. These results should be interpreted with caution
because of the relatively small numbers and the large standards
deviations with a number of out layers who have probably
influenced the results for each subgroup, and because there are
several reasons that may account for such differences. The use of
the % predicted helped to reduce the risk that age or height could
have influenced the analysis in relatively small groups because of
growth. We did not specifically addressed the issue of steroids as
this was addressed in our recent paper on the same cohort, but,
with few exceptions, all the boys in the present study were on
steroids and with a similar distribution of daily and intermittent
regimes in each subgroup. When we excluded from the analysis
the boys who were not on steroids, the level of significance did not
change.
It is not completely surprising that the deletions eligible for
skipping of the exon 44 had better results than other subgroups as
there is reported evidence that out-of-frame deletions around
exons 44 can have a high rate of ‘‘exceptions’’ to the reading frame
Figure 4. Mean 12 month changes (left panel) and % predicted (right panel) of 6MWD in individual subgroups.
doi:10.1371/journal.pone.0083400.g004
Figure 3. Twelve month changes of 6MWD: in each graph the individual results obtained in individual subgroups (eligible for
skipping exon 44, 45, 51 and 53) are plotted against those found in the whole DMD color.
doi:10.1371/journal.pone.0083400.g003
6MWT in DMD
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rule resulting in a quite wide range of clinical severity, including
intermediate (IMD) or even BMD and therefore better baseline
values on the 6MWT [21,22]. Furthermore it has also been
recently suggested that DMD patients with deletions flanking exon
44 have significantly higher percentage of revertant fibres and
traces of low-level dystrophin expression than those with deletions
surrounding exon 51 [23], and this could also explain the relatively
better baseline values.
Further help in clarifying the variability of findings may also
come from the analysis of specific genotypes, such as the SPP1or
the LTBP4 genotype, that have recently been found to contribute
to predict the severity of the phenotype in DMD [24] [25].
This study provides for the first time information on the natural
history of distinct groups of mutations using the same outcome
measure (6MWT) and the same time frame (12 months), that have
been chosen in the recent and ongoing clinical trials in ambulant
DMD [12,26]. Another advantage of this study is that we included
a larger proportion of boys below the age of 7 years than in the
other recent natural history studies, therefore providing further
information of the 6MWD in the younger children who, as also
suggested by the regulatory authorities, may be a good target for
efficacy studies as their muscles are more preserved. The larger
number of younger children is also reflected in the results, showing
less negative 12 month 6MWD changes than those previously
obtained in cohorts with a smaller proportion of DMD boys
younger than 7 years [15,16].
In conclusion our results showed some differences among
subgroups, that were more obvious at baseline, with patients
eligible for skipping 44 having overall better results than the
others. The difference between individual subgroups (expecially 44
versus 45 or 53) however was bigger than the difference between
each subgroup and the whole cohort of DMD boys. The 12 month
mean changes in each subgroup were all within a relatively narrow
range from the mean of the whole DMD cohort as also proved by
the test for heterogeneity that did not show a significant difference.
Rather than focusing on the non-significance of the heterogeneity
test among subgroups that is favoured by the relatively small
numbers of subjects included in each subgroup, the important
issue is that this paper for the first time provides an estimate of the
size of the variations that can be expected in subgroups due to the
different mutations in the dystrophin gene. This information will
be of help at the time of designing clinical trials with small
numbers of eligible patients.
This paper also suggest that age, height and steroids cannot fully
explain the variability of the findings and further studies on larger
cohorts, exploring modifying genes and correlating functional
abilities with dystrophin analysis are needed to further clarify the
variability observed in the whole cohort and identify criteria for
stratification and possible adjustments.
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